A fixed-dose combination inhaler containing Levosalbutamol (the active R-enantiomer of Salbutamol) and Ipratropium Bromide. Levosalbutamol is a selective short-acting beta2-adrenergic agonist (SABA) providing rapid bronchodilation, while Ipratropium is a short-acting muscarinic antagonist (SAMA) that provides complementary bronchodilation via a different pathway. This combination is synergistic, offering superior bronchodilation compared to monotherapy, particularly in patients with moderate to severe airflow obstruction. It is a cornerstone in the management of acute exacerbations of obstructive airway diseases in the Indian clinical setting.
Adult: The standard dose is 2 puffs (each puff containing Levosalbutamol 0.63mg + Ipratropium 500mcg) via MDI, inhaled 4 times a day as needed for symptom relief or during exacerbations. Maximum: 12 puffs in 24 hours. For Respimat inhaler: 1 puff (equivalent dose) 4 times daily.
Note: 1. Shake the MDI canister well before use. 2. Exhale fully. 3. Place mouthpiece between lips, forming a tight seal. 4. Activate the inhaler at the start of a slow, deep inhalation. 5. Hold breath for 5-10 seconds. 6. Wait at least 30-60 seconds before the second puff. 7. Rinse mouth with water after use to prevent oral thrush and systemic absorption. Use a spacer device if coordination is poor.
The combination works synergistically via two distinct pathways to achieve bronchodilation. Levosalbutamol stimulates intracellular adenylate cyclase via beta2-adrenergic receptors, increasing cyclic AMP (cAMP), leading to relaxation of bronchial smooth muscle. Ipratropium competitively inhibits acetylcholine at muscarinic (M3) receptors on bronchial smooth muscle and submucosal glands, blocking vagally mediated bronchoconstriction and mucus secretion. This dual blockade of sympathetic and parasympathetic pathways provides more complete and potent bronchodilation than either agent alone.
Pregnancy: Pregnancy Category C (US FDA). Adequate and well-controlled studies in pregnant women are lacking. Use only if potential benefit justifies potential risk to the fetus. Levosalbutamol may inhibit labor. Ipratropium is poorly absorbed systemically. Consult physician.
Driving: May cause dizziness, blurred vision, or nervousness. Patients should not drive or operate machinery until they know how the medication affects them.
| Other Beta-Adrenergic Agonists (Oral/Inhaled) | Additive sympathomimetic effects, increased risk of tachycardia, hypokalemia, arrhythmias. | Major |
| Beta-Adrenergic Blockers (e.g., Propranolol) | Antagonizes bronchodilator effect of Levosalbutamol; may induce severe bronchospasm in asthmatics. | Major |
| Diuretics (Loop/Thiazide) | Concomitant use with high-dose beta-agonists may potentiate hypokalemia. | Moderate |
| Monoamine Oxidase Inhibitors (MAOIs) & Tricyclic Antidepressants (TCAs) | May potentiate the cardiovascular effects (hypertension, tachycardia) of Levosalbutamol. | Moderate |
| Xanthine derivatives (Theophylline) | Additive cardiovascular stimulant effects; increased risk of arrhythmias. | Moderate |
| Anticholinergic drugs (e.g., Tiotropium, Aclidinium, Atropine, Antihistamines, Phenothiazines) | Additive anticholinergic side effects (dry mouth, urinary retention, constipation, blurred vision). | Moderate |
| Digoxin | Hypokalemia from beta-agonists may increase risk of digoxin toxicity. | Moderate |
| Corticosteroids (Systemic) | May enhance hypokalemic effect of beta-agonists. | Moderate |
Same composition (Levosalbutamol (0.63mg) + Ipratropium (500mcg)), different brands: